Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity-A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

被引：1
|
作者：
Aronne, Louis
Harris, M. Scott
Roberts, M. S.
Suschak, John J.
Tomah, Shaheen
Kasper, Jonathan
He, Liang
Yang, Jay
Frias, Juan P.
Browne, Sarah K.
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-262-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
262-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
    Wan, Haijun
    Xu, Nuo
    Wang, Lijuan
    Liu, Yaping
    Fatahi, Somaye
    Sohouli, Mohammad Hassan
    Guimaraes, Nathalia Sernizon
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
  • [32] Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist
    Roux, Carel W. Ie
    Steen, Oren
    Lucas, Kathryn J.
    Startseva, Elena
    Unseld, Anna
    Hussain, Samina Ajaz
    Hennige, Anita M.
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1773 - 1782
  • [33] A triple GIP, GLP-1 and glucagon receptor agonist, retatrutide, decreases inflammatory CV risk biomarkers in people with overweight or obesity, with or without type 2 diabetes
    Ruotolo, G.
    Harris, C.
    Lin, Y.
    Thomas, M. K.
    Qu, Y.
    Wilson, J.
    Duffin, K.
    Hartman, M. L.
    Coskun, T.
    Milicevic, Z.
    Haupt, A.
    DIABETOLOGIA, 2024, 67 : S82 - S82
  • [34] Liraglutide, a Once-Daily Human GLP-1 Analog, Reverses Indices of Prediabetes in Obese Subjects: A Randomized Placebo-Controlled 20-Week Trial
    Finer, Nick
    Al Hakim, Mazin
    Astrup, Arne
    Harper, Angela
    Lean, Mike
    Niskanen, Leo
    Rasmussen, Mads F.
    Rissanen, Aila
    Roessner, Stephan
    Van Gaal, Luc
    DIABETES, 2009, 58 : A443 - A444
  • [35] Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial
    Ebdrup, Bjorn H.
    Broberg, Brian V.
    Ishoy, Pelle L.
    Bak, Nikolaj
    Andersen, Ulrik B.
    Jorgensen, Niklas R.
    Holst, Jens J.
    Knop, Filip K.
    Glenthoj, Birte Y.
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1327 - 1328
  • [36] Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial
    Mojca Jensterle
    Simona Ferjan
    Tadej Battelino
    Jernej Kovač
    Saba Battelino
    Dušan Šuput
    Andrej Vovk
    Andrej Janež
    Trials, 22
  • [37] Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial
    Jensterle, Mojca
    Ferjan, Simona
    Battelino, Tadej
    Kovac, Jernej
    Battelino, Saba
    Suput, Dusan
    Vovk, Andrej
    Janez, Andrej
    TRIALS, 2021, 22 (01)
  • [38] Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD
    Parker, Victoria E.
    Hoang, Thuong
    Schlichthaar, Heike
    Gibb, Fraser W.
    Wenzel, Barbara
    Posch, Maximilian G.
    Chang, Yi-Ting
    Petrone, Marcella
    Hansen, Lars
    Ambery, Philip
    Heerspink, Hiddo L.
    Mccrimmon, Rory J.
    Jermutus, Lutz
    DIABETES, 2021, 70
  • [39] Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight-A Phase 2 Study
    Wharton, Sean
    Blevins, Thomas
    Connery, Lisa B.
    Rosenstock, Julio
    Raha, Sohini
    Mather, Kieren J.
    Haupt, Axel
    Robins, Deborah A.
    Pratt, Edward J.
    Kazda, Christof M.
    Konig, Manige
    DIABETES, 2023, 72
  • [40] Renal Effects of 12-Week GLP-1 Receptor Agonist Liraglutide or DPP-4 Inhibitor Sitagliptin Treatment in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Diamant, Michaela
    Joles, Jaap A.
    Van Raalte, Daniel H.
    DIABETES, 2016, 65 : A140 - A140
12345